

# OPTIMIZING ADHERENCE TO THERAPY IN HEPATITIS C: CHALLENGES AND EMERGING STRATEGIES

Supplement 3 to Volume 71, May 2004

## SUPPLEMENT EDITOR

ZOBAIR M. YOUNOSS, MD, MPH  
Inova Fairfax Hospital

## ASSOCIATE EDITOR

WILLIAM D. CAREY, MD  
The Cleveland Clinic

## ASSOCIATE EDITOR

ANTHONY S. TAVILL, MD  
MetroHealth Medical Center

## CONTENTS

Foreword .....	S2
The evolving treatment of chronic hepatitis C: Where we stand a decade out .....	S3
SHERIF SAADEH, MD, AND GARY L. DAVIS, MD	
Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration .....	S8
KEYUR PATEL, MD, AND JOHN G. MCHUTCHISON, MD	
Retreatment of patients who do not respond to initial therapy for chronic hepatitis C .....	S13
MITCHELL L. SHIFFMAN, MD	
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: Anemia, neutropenia, and thrombocytopenia .....	S17
JANUS P. ONG, MD, AND ZOBAIR M. YOUNOSS, MD, MPH	
The role of hematopoietic growth factors in special populations with chronic hepatitis C: Patients with HIV coinfection, end-stage renal disease, or liver transplantation .....	S22
STEVAN A. GONZALEZ, MD, AND IRA M. JACOBSON, MD	
Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C .....	S27
CATHERINE C. CRONE, MD; GEOFFREY M. GABRIEL, MD; AND THOMAS N. WISE, MD	
The role of physician extenders in managing patients with chronic hepatitis C .....	S33
HARPREET GUJRAL, RN, MSN, CRNP; CARLA VISCOMI, RN, BSN; AND ROCHELLE COLLANTES, MD, MPH	

This publication is supported by an unrestricted educational grant from Amgen Inc.

Topics and editors for supplements to the *Cleveland Clinic Journal of Medicine* are determined by the *Journal's* editor-in-chief and staff. Supplement editors are chosen for their expertise in the topics discussed and are responsible for the scientific quality of supplements, including the review process. The *Journal* ensures that supplement editors and authors fully disclose any relationships with industry, including the supplement underwriter. For full guidelines on grant-supported supplements to the *Journal*, go to [www.ccejm.org/pdf/guidelines.pdf](http://www.ccejm.org/pdf/guidelines.pdf).

Author financial conflict-of-interest disclosures appear within the authors' respective articles.

Copyright © 2004 The Cleveland Clinic Foundation.

The statements and opinions expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of The Cleveland Clinic Foundation, its Board of Trustees, or Amgen Inc.

The *Cleveland Clinic Journal of Medicine* (ISSN 0891-1150) is published 12 times yearly by The Cleveland Clinic Foundation.

Subscription rates: U.S. and possessions: personal \$98; institutional \$124; single copy/back issue \$16. Foreign: \$124; single copy/back issue \$16. Institutional (mul-

tiplier rate) applies to libraries, schools, hospitals, and federal, commercial, and private institutions and organizations. Individual subscriptions must be in the names of, billed to, and paid by individuals.

Postmaster address changes: *Cleveland Clinic Journal of Medicine*, NA32, 9500 Euclid Avenue, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): (216) 444-2661 (phone); (216) 444-9385 (fax); [ccjm@ccf.org](mailto:ccjm@ccf.org) (e-mail); [www.ccejm.org](http://www.ccejm.org) (Web)

Printed in USA.

